Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) Receives Average Rating of “Moderate Buy” from Brokerages

Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) has been given an average recommendation of “Moderate Buy” by the six brokerages that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $55.80.

A number of equities analysts have recently commented on PTHS shares. Piper Sandler started coverage on shares of Pelthos Therapeutics in a research report on Friday, February 27th. They set an “overweight” rating and a $48.00 target price on the stock. Zacks Research raised Pelthos Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 24th. HC Wainwright reaffirmed a “buy” rating and set a $60.00 target price on shares of Pelthos Therapeutics in a research report on Thursday, March 19th. Oppenheimer upped their target price on Pelthos Therapeutics from $62.00 to $66.00 and gave the stock an “outperform” rating in a report on Friday, May 15th. Finally, Cantor Fitzgerald started coverage on Pelthos Therapeutics in a research note on Wednesday, April 1st. They set an “overweight” rating and a $50.00 price target on the stock.

Institutional Investors Weigh In On Pelthos Therapeutics

Several hedge funds have recently modified their holdings of the business. Persistent Asset Partners Ltd lifted its stake in shares of Pelthos Therapeutics by 150.0% during the 4th quarter. Persistent Asset Partners Ltd now owns 6,007 shares of the company’s stock worth $186,000 after purchasing an additional 3,604 shares during the last quarter. Pale Fire Capital SE raised its stake in shares of Pelthos Therapeutics by 59.5% in the first quarter. Pale Fire Capital SE now owns 12,919 shares of the company’s stock worth $271,000 after purchasing an additional 4,819 shares during the last quarter. Millennium Management LLC acquired a new position in Pelthos Therapeutics in the 4th quarter worth approximately $343,000. Geode Capital Management LLC boosted its holdings in shares of Pelthos Therapeutics by 31.9% in the 4th quarter. Geode Capital Management LLC now owns 13,625 shares of the company’s stock valued at $422,000 after acquiring an additional 3,295 shares during the last quarter. Finally, Knott David M Jr boosted its holdings in Pelthos Therapeutics by 9.3% in the first quarter. Knott David M Jr now owns 21,073 shares of the company’s stock valued at $443,000 after purchasing an additional 1,792 shares during the last quarter. Hedge funds and other institutional investors own 77.96% of the company’s stock.

Pelthos Therapeutics Price Performance

Shares of NYSEAMERICAN PTHS opened at $27.11 on Thursday. The stock has a 50-day moving average price of $23.77. Pelthos Therapeutics has a 1 year low of $9.00 and a 1 year high of $54.29. The company has a current ratio of 2.79, a quick ratio of 1.86 and a debt-to-equity ratio of 1.41. The company has a market capitalization of $94.34 million, a P/E ratio of -1.31 and a beta of 3.29.

Pelthos Therapeutics (NYSEAMERICAN:PTHS) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($3.09) EPS for the quarter. The business had revenue of $10.91 million during the quarter. As a group, equities research analysts expect that Pelthos Therapeutics will post -11.7 EPS for the current year.

About Pelthos Therapeutics

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).